Thomas Fuller | SOPA Photos | Lightrocket | Getty Photos
UniQure must run one other examine to show that its gene remedy “really helps folks with Huntington’s illness,” a senior U.S. Meals and Drug Administration official mentioned on a name with reporters Thursday.
The official, who requested anonymity earlier than discussing delicate info, confirmed the company has requested the corporate to run a placebo managed trial of its remedy, which is run instantly into the mind. UniQure has mentioned that sort of examine is not moral as a result of it could require placing folks below basic anesthesia for hours, a characterization the official disputed.
“So what is absolutely occurring? UniQure is the most recent firm to make a failed remedy for Huntington’s sufferers,” the official mentioned. “They seemingly acknowledge or perceive at some deep stage that their trial failed years in the past, and as a substitute of doing the suitable factor and operating the right scientific examine, UniQure is performing a distorted or manipulated comparability within the thoughts of FDA.”
The feedback mark the most recent growth in a messy public spat between UniQure and the FDA, and because the company comes below fireplace for plenty of current drug approval utility rejections, together with some the place corporations have accused it of going again on earlier steering. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Fast final week seemingly criticized UniQure’s gene remedy for Huntington’s illness. Makary did not identify UniQure however described its remedy.
UniQure then accused the FDA of reversing its stance that the corporate’s scientific trial information could be ample to hunt approval. UniQure’s examine used an out of doors database to measure how sufferers with Huntington’s illness would possibly decline with out remedy, often called an exterior management. UniQure has mentioned it would not be possible to run a real randomized, double-blind placebo-controlled examine, thought-about the gold commonplace, as a result of it would not be moral to make folks bear a sham hours-long mind surgical procedure.
The FDA official mentioned the company “by no means agreed to just accept this distorted comparability” and the FDA “by no means makes such assurances.” As an alternative, the “FDA will at all times say, ‘Nicely, we’ve got to see the info once we get it.'”
UniQure did not instantly remark.
The corporate’s inventory rose greater than 10% on Thursday and has fallen 58% this yr as of Thursday afternoon.
